| Metric | Value (₹ Cr) | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 85.21 | 24.4% | 22.7% |
| Total Income | 85.41 | 24.1% | 22.7% |
| Expenditure | 78.54 | 23.7% | 20.1% |
| PBT | 6.87 | 29.5% | 63.8% |
| Net Profit | 5.14 | 33.9% | 63.9% |
| OPM | 9.91% | 1.37pp | 2.82pp |
| NPM | 6.02% | 0.44pp | 1.52pp |
| EPS | 7.38 | 33.9% | 64.0% |
Strong margins validated; domestic ramp-up ahead with execution risk
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
First earnings call; Q1 numbers match stated figures. No prior guidance to assess track record; domestic diversification unproven.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Q1 delivers strong margin expansion (NPM 4.2%→6.0%) and 22.7% revenue growth, validating management execution. However, FY27 guidance of 15–20% growth signals deceleration, and domestic facility ramp-up is nascent (₹15–20 Cr on ₹85+ Cr base). Key risk: 60–65% concentration in top 10 customers and execution dependency on India B2B/B2C entry.
₹85.21 Cr
Revenue · +22.7% YoY₹5.14 Cr
Reported PAT · +63.9% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Revenue 22.7% YoY growth to ₹85.21 Cr
METDelivered ₹85.2 Cr, +22.7% YoY (₹69.44 Cr Q1 FY26)
PAT 63.9% YoY growth to ₹5.14 Cr
METDelivered ₹5.1 Cr, +63.9% YoY; NPM 6.0% delivered vs 6.03% stated
EBITDA margin improved to 10.14% from 7.35%
METEBITDA ₹8.64 Cr at 10.14% margin; prior ₹5.10 Cr at 7.35%. Operational efficiency gain corroborated.
FY27 guidance 15–20% growth (predominantly export)
CorroboratedStated explicitly; implies Q1's 22.7% will decelerate, new facility minimal contribution (₹15–20 Cr from domestic)
New facility ₹250–300 Cr incremental revenue at peak capacity
UnverifiedManagement guidance on 125–150 kg capacity studded jewelry mix (3–4 year ramp). Unverified, aspirational.
Earnings quality
What changed since the last call
Strategic pivot to India domestic
NewFirst time: new ₹27 Cr facility in Andheri for domestic B2B/B2C. Prior: export-only (40 years, 85–90% Middle East). Major diversification.
Lab-grown jewelry focus expansion
UpgradeCurrently <7% of revenue (mostly US), targeting significant domestic contributor via B2C. Nascent category in India; upside unproven but tailwind cited.
US market tariff impact stabilizing
UpgradeRevenue from USA fell from 20–30% (prior year) to <10% due to tariff headwinds. Now 'better performance' in FY27; recovery modest but positive.
Customer retention in Middle East
Maintained85–90% of revenue still from Middle East (UAE, Saudi, Qatar, Kuwait, Bahrain). 20-year relationships intact; no major losses or gains mentioned.
The Q&A
Analysts pressed on specifics: domestic strategy clarity (answered), competitor positioning (hedged—nascent market), capex/WC needs (answered: ₹27 Cr raised suffices), and long-term margin targets (deferred pending domestic ramp proof). Management held firm on guidance but cautious tone prevailed.
Domestic expansion strategy — Dhaval Pandya, Areeza India
AnsweredTwofold: B2B supply to major retail chains (leveraging Middle East relationships) + B2C lab-grown jewelry focus. Positioning on studded jewellery vs competitors' plain gold.
Export market model — Dhaval Pandya, Areeza India
AnsweredNo subsidiaries. Direct B2B to wholesalers, distributors, retailers across Middle East, USA, Europe. Asset-light model.
Lab-grown competition — Dhaval Pandya, Areeza India
PartialNo specific named competitors. Market nascent; many entrants (branded retail + traditional jewelers). Big market ahead for multiple players globally.
Hedging policy — Dhaval Pandya, Areeza India
AnsweredNatural hedge for gold (import/export at same price). Forward contracts for diamonds 4–6 months based on receivables planning. Comprehensive coverage.
FY27–FY30 guidance — Dhaval Pandya, Areeza India
AnsweredFY27: 15–20% (mostly export). By 2030: 50% domestic target; current ₹280 Cr exports + domestic = ₹550–600 Cr rough estimate.
New capacity revenue potential — Ramesh, Millennium Capital
Answered₹250–300 Cr incremental capacity at peak (mix of caratage/metals/lab-grown). Mix dependent on gold pricing. Conservative estimate.
FY29 total revenue projection — Ramesh, Millennium Capital
AnsweredRough calc: ₹280 Cr exports + 50% split = ₹550–600 Cr total.
Customer concentration — Ramesh, Millennium Capital
AnsweredTop 10: 60–65% of revenue.
Lab-grown revenue mix — Ramesh, Millennium Capital
Answered<5–7% currently. Mostly US market. Middle East not active yet. Targeting India domestic as major contributor.
Lab-grown revenue targets 3–5 years — Ramesh, Millennium Capital
PartialHoping lab-grown 'significant contributor' in domestic; US exports improving this year after tariff hit. No specific $ target given.
Design-to-production conversion — Ramesh, Millennium Capital
AnsweredAll 500 are commercial-level (not prototype/creative). Some get multiple orders, some fewer. All production-ready.
Inventory & receivables in domestic — Ramesh, Millennium Capital
AnsweredExport: 10–11x inventory. Domestic expected similar or better (more competitive credit in export). Domestic should be easier to manage.
EBITDA margin targets — Ramesh, Millennium Capital
PartialExport: hopeful to maintain. Domestic: EBITDA 'tighter initially' due to marketing push, but will reach similar margins over time.
Export revenue geography — Ramesh, Millennium Capital
AnsweredMiddle East: 85–90% of total (UAE, Saudi, Qatar, Kuwait, Bahrain). 20-year relationships, robust and consistent.
Hormuz geopolitical impact — Ramesh, Millennium Capital
AnsweredMinimal. Only Feb–Mar 2026 shipping disruption (~1 month). Air ops resumed after. Business and revenue not affected; numbers show strength.
US revenue % and tariff impact — Ramesh, Millennium Capital
AnsweredNow <10% (down from 20–30% prior year). Tariff headwinds last year. Now stabilizing; better performance FY27.
New export markets — Ramesh, Millennium Capital
AnsweredNo. Geopolitical risks high. Focusing on India domestic instead—better control, higher consumption. Export hedged by tailwinds.
Long-term vision and execution milestones — Ramesh, Millennium Capital
Answered40-year established company pivoting domestic. Lab-grown and retail opportunity in India. Raising capital, starting earnings call = serious commitment. Revenue >2x in 5 years expected.
New facility ramp speed — Prateek Shetty, A.Square
AnsweredLive now. Making samples for clients. No high volume current year. Seasonal ramp expected. Not waiting—active pitching phase.
Domestic facility revenue FY27 — Prateek Shetty, A.Square
Answered₹15–20 Cr expected. Three years out: ₹250 Cr at peak capacity.
B2C launch timing — Prateek Shetty, A.Square
AnsweredDiwali current year (Oct–Nov 2026) or pre-Diwali. Retail lounge (3rd floor) will kick-start B2C.
Competitive positioning vs peers — Prateek Shetty, A.Square
AnsweredDifferent model than listed peers. Most peers do plain gold/CZ/diamonds. Golkunda focuses studded jewellery (natural + lab-grown). Differentiated.
B2B vs B2C revenue split — Prateek Shetty, A.Square
PartialB2C insignificant FY27. Over time, will become significant contributor. Requires brand-building time. No specific % target.
B2C margins — Prateek Shetty, A.Square
PartialB2C should be 'definitely better' in margin. But too early to quantify—just starting.
Guidance
FY27: 15–20% growth (predominantly export-driven)
MediumNew facility expected ₹15–20 Cr (3–8% of revenue). Domestic ramping; export stable. Conservative vs Q1's 22.7%.
By FY29: ₹550–600 Cr total (50% domestic target by 2030)
MediumCurrent ₹280 Cr exports + estimated domestic buildup. Assumes successful B2B/B2C execution. 2–3 year timeline. Aspirational.
New facility peak capacity: ₹250–300 Cr incremental (3–4 years)
LowStudded jewelry mix (carats, metals, lab-grown). Dependent on gold pricing and market mix. 'Shaded' by macro factors.
Export EBITDA: maintain current 10.14% margin level
MediumManagement states hopeful to maintain. No specific target. Tariffs stable, costs under control.
Domestic EBITDA: initially tighter, convergence to export levels over time
LowMarketing push and ramp inefficiencies will compress margins initially. Long-term parity expected but unquantified timeline.
B2C margins: 'definitely better' than B2B, but too early to detail
LowAspirational. B2C upside unclear; brand building takes time. No baseline provided.
₹27 Cr preferential allotment covers facility expansion and working capital
HighCapital already raised. Domestic facility operational; additional capex for 3rd floor retail lounge + WC for scaling.
Risks the call surfaced
Customer concentration
HighTop 10 customers account for 60–65% of total revenue. Loss of single major retail partner would materially impact revenue. No customer diversification mentioned.
Domestic execution
MediumNew facility (6 months old) still in sample/pitching phase. Expected ₹15–20 Cr FY27 contribution is 18–23% of new capacity potential. B2C launch Diwali 2026 unproven. Execution unvalidated.
Tariff and geopolitical exposure
MediumUS revenue fell from 20–30% to <10% due to tariffs. Hormuz shipping disruption (Feb–Mar 2026) caused 1-month pause. Management pivoting to domestic to hedge geopolitical risk.
Lab-grown market scaling
MediumLab-grown <7% of revenue currently (mostly US). India market nascent; branded retail and traditional jewelers just entering. No specific revenue targets for lab-grown 3–5 years. Consumer adoption unproven.
Working capital and cash flow
LowExport inventory 10–11x cycles. Domestic expected similar or better. WC management critical as domestic scales. No cash flow statement provided.
Management
Score 7/10. Clear and structured. First earnings call; management took time to intro company, strategy, business model. Direct on most Q&A specifics (revenue, margins, guidance). Some hedging on lab-grown targets, B2C margins, and EBITDA trajectory. Delivered Q1 numbers matching stated figures exactly (revenue ₹85.21 Cr, PAT ₹5.14 Cr). Margin expansion 4.2%→6.0% NPM validates cost discipline. New facility operational on timeline (6 months). No prior guidance track record (first call).
1 · Diwali 2026 (Oct–Nov)
B2C brand launch at new Andheri retail lounge; early brand-building phase.
2 · Q2 FY27 (Sep–Oct 2026)
Domestic B2B sample pitching cycles complete; first orders expected from organized retail chains.
3 · FY28 (Apr 2027–Mar 2028)
New facility 3rd floor retail lounge operational; B2C revenue ramp accelerates.
Key risk: 60–65% concentration in top 10 customers and execution dependency on India B2B/B2C entry.
Margin Expansion Strong, but Domestic Execution Risk Shadows the Pivot
Q1 delivered across the board—margins expanded sharply, growth surged—but management's FY27 guidance of 15–20% signals deceleration. The call reveals the deeper story: a 40-year export business is pivoting to India domestic, and that ramp is nascent and unproven.
₹85.2 Cr
+22.7% YoY
₹5.1 Cr
+63.9% YoY
6.0%
+180 bps YoY
15–20%
vs Q1's 22.7%
On the headline, Q1 is a blowout. Revenue grew 22.7%, PAT jumped 63.9%, and both margins expanded sharply (NPM +180 bps to 6.0%, EBITDA +279 bps to 10.14%). But management's FY27 guidance of 15–20% growth is a reality check: the new domestic facility will contribute only ₹15–20 Cr this year (18–23% of peak capacity), while the bulk of revenue (85–90%) still comes from the export-only, 40-year-old Middle East operation. This quarter is profitable momentum masking a harder pivot ahead.
Margin expansion validates operational efficiency
The EBITDA margin jump from 7.35% to 10.14% (279 bps) and NPM lift from 4.2% to 6.0% (180 bps) are not one-time driven. This is operational: better cost control, capacity utilization, and export margins holding despite tariff headwinds (US revenue fell from 20–30% to <10%, now stabilizing). No extraordinary items or fair-value gains muddy the read. The margin story is clean, but it's built on a small base (Q1 ₹85.2 Cr) and export-heavy (Middle East 85–90%).
Management's claims—what holds up
Revenue 22.7% YoY to ₹85.21 Cr
SupportedDelivered ₹85.2 Cr exactly (Q1 FY26: ₹69.44 Cr). Numbers match to paise.
PAT 63.9% YoY to ₹5.14 Cr, NPM 6.0%
SupportedDelivered ₹5.1 Cr; NPM 6.0% as stated. Consistent across the P&L.
EBITDA margin improved to 10.14% from 7.35%
SupportedEBITDA ₹8.64 Cr vs ₹5.10 Cr prior year. Operational efficiency corroborated.
FY27 growth guidance 15–20% (predominantly export-driven)
CorroboratedStated explicitly. Implies Q1's 22.7% decelerates as domestic facility ramps at 18–23% of peak.
New facility ₹250–300 Cr incremental capacity at peak (3–4 years)
UnverifiedAspirational. Dependent on gold mix, market adoption, and macro conditions. Unverified.
What changed on this call
This is the inflection. After 40 years of export-only, Golkunda has launched its first domestic manufacturing facility in Andheri (₹27 Cr capital raised via preferential allotment). The facility is operational and making samples; ₹15–20 Cr revenue expected FY27, ramping to ₹250–300 Cr peak capacity over 3–4 years. Lab-grown jewelry is being elevated from US tariff exposure is retreating—revenue fell from 20–30% to Middle East remains the anchor (85–90% of revenue, 20-year relationships), but the company is explicitly diversifying away from export concentration.
The debate
The bull-bear ledger
Q1 numbers delivered exactly; no misses or one-time gains
Margin expansion (NPM +180 bps, EBITDA +279 bps) validates cost discipline
New facility operational 6 months; samples/pitching active (not aspirational)
₹27 Cr capital raised; no near-term financing risk
40-year export track record; Middle East relationships stable
Customer concentration 60–65% top 10; single-client risk material
FY27 guidance 15–20% signals deceleration from Q1's 22.7%
Domestic facility only ₹15–20 Cr FY27 (~18–23% of peak capacity)
Lab-grown <7% revenue; India B2C market unproven
Tariff/geopolitical risk; US revenue fell 20–30% to <10%
Risks, ranked by how much they should concern a holder
Customer concentration: top 10 = 60–65% of revenue
HighLoss of single major retail customer materially impacts revenue. Diversification unproven.
Domestic execution unproven
MediumFacility ₹15–20 Cr FY27 (18–23% of peak). B2B/B2C strategy nascent; ramp depends on retail chain adoption and brand-building. 3+ year timeline.
Lab-grown scaling
Medium<7% of revenue currently (mostly US). India market nascent; no quantified revenue targets 3–5 years. Consumer adoption unproven.
Tariff and geopolitical volatility
MediumUS revenue fell 20–30% to <10% due to tariffs. Hormuz shipping disruption (Feb–Mar 2026, 1 month). Further trade escalation risks export.
Working capital and cash flow cycles in domestic
LowExport inventory 10–11x; domestic unproven but expected similar or better. ₹27 Cr capital raised provides cushion.
How the street is positioned
Post-result momentum held. The day-1 pop of +3.93% extended to +7.41% by day 3, settling at +5.63% by day 5 (announcement close ₹274.55 → current ₹288.2). Retail delivery 78.1% day-1 shows strong retail participation. Stock is overbought (RSI 80.5) and elevated vs 52-week SMA20 (₹265.09), SMA50 (₹260.85), SMA200 (₹241.07)—trend bullish but momentum exhaustion risk brewing. Ownership is stuck: promoter 72.81%, FII 0%, DII 0%. This is a mom-and-pop + promoter story; zero institutional backing. The retail enthusiasm is unanchored by foreign or domestic institutional capital, meaning the move faces correction risk if guidance misses or domestic ramp falters.
What to watch next
1 · Diwali 2026 B2C launch (Oct–Nov 2026)
Retail lounge at Andheri facility opens for brand-building. Revenue immaterial FY27, but timing and retail traction are execution signals.
2 · Q2 FY27 domestic B2B ramp (Sep–Oct 2026)
Sample pitching complete. First meaningful orders from organized retail chains expected. Quarterly guidance hit = proof of execution.
3 · FY28 facility 3rd floor retail opening (Apr 2027)
Concrete milestone. Retail lounge fully operational. B2C revenue ramp accelerates. Peak facility capacity ₹250–300 Cr over 3–4 years.
Not a step-change quarter, but a profitable setup for a multi-year pivot. Margins expanded sharply (NPM +180 bps, EBITDA +279 bps), revenue grew 22.7% organically. Guidance deceleration (15–20% FY27 vs Q1's 22.7%) is honest—it reflects domestic ramp headwinds. Execution risk is real (customer concentration 60–65% top 10, B2B/B2C unproven, lab-grown <7% revenue). But so is the opportunity. The street is overbought (RSI 80.5) with zero institutional backing (promoter 72.81%, FII/DII 0%). Momentum held post-result (+5.63% by day 5) but stock faces correction risk if domestic stumbles.
The number to track: domestic facility revenue. Expect ₹15–20 Cr FY27 (18–23% of peak capacity), ramping to ₹250–300 Cr over 3–4 years. That trajectory, and B2B order ramp, resolve the execution story.